Lars Hangartner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3911221/publications.pdf

Version: 2024-02-01

35 papers	4,387 citations	304743 22 h-index	395702 33 g-index
41 all docs	41 docs citations	41 times ranked	5493 citing authors

#	Article	IF	Citations
1	Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement. Journal of Virology, 2022, 96, JVI0168921.	3.4	0
2	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcÎ³RIIb on Liver Sinusoidal Endothelial Cells by Endocytosis. Journal of Immunology, 2021, 206, 1284-1296.	0.8	6
3	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Science Translational Medicine, 2021, 13, .	12.4	23
4	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. Journal of Virology, 2021, 95, e0079621.	3.4	6
5	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. Cell, 2020, 183, 185-196.e14.	28.9	25
6	Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design. Current Topics in Microbiology and Immunology, 2020, 428, 31-87.	1.1	0
7	Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. Cell Reports, 2020, 30, 3755-3765.e7.	6.4	81
8	Public Endowment of B Cells. Immunity, 2019, 51, 601-603.	14.3	0
9	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	14.3	153
10	Reprogramming the antigen specificity of B cells using genome-editing technologies. ELife, 2019, 8, .	6.0	69
11	Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. Cell Reports, 2018, 23, 90-99.	6.4	80
12	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. Immunity, 2018, 49, 288-300.e8.	14.3	175
13	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annual Review of Immunology, 2016, 34, 635-659.	21.8	500
14	The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. Aids, 2015, 29, 1803-1810.	2.2	8
15	Heterosubtypic Antibodies to Influenza A Virus Have Limited Activity against Cell-Bound Virus but Are Not Impaired by Strain-Specific Serum Antibodies. Journal of Virology, 2015, 89, 3136-3144.	3.4	23
16	Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. Clinical Infectious Diseases, 2014, 59, 1386-1393.	5.8	9
17	Alternative Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a V _H 3-30-Encoded Heterosubtypic Antibody. Journal of Virology, 2014, 88, 7083-7092.	3.4	62
18	Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs. PLoS Pathogens, 2013, 9, e1003106.	4.7	172

#	Article	IF	Citations
19	Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. Journal of Immunology, 2012, 189, 4816-4824.	0.8	57
20	Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology. Retrovirology, 2012, 9, .	2.0	1
21	Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. PLoS Pathogens, 2009, 5, e1000433.	4.7	475
22	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Medicine, 2009, 15, 951-954.	30.7	509
23	Recombination of Retrotransposon and Exogenous RNA Virus Results in Nonretroviral cDNA Integration. Science, 2009, 323, 393-396.	12.6	131
24	Antibodies against viruses: passive and active immunization. Current Opinion in Immunology, 2008, 20, 486-492.	5.5	41
25	Absence of CTL Responses to Early Viral Antigens Facilitates Viral Persistence. Journal of Immunology, 2008, 180, 3113-3121.	0.8	22
26	Attenuated measles virus as a vaccine vector. Vaccine, 2007, 25, 2974-2983.	3.8	74
27	Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nature Medicine, 2007, 13, 1316-1323.	30.7	54
28	Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 2007, 449, 101-104.	27.8	828
29	Natural IgE Production in the Absence of MHC Class II Cognate Help. Immunity, 2006, 24, 329-339.	14.3	103
30	Antiviral antibody responses: the two extremes of a wide spectrum. Nature Reviews Immunology, 2006, 6, 231-243.	22.7	275
31	Parameters governing exhaustion of rare T cell-independent neutralizing IgM-producing B cells after LCMV infection. European Journal of Immunology, 2006, 36, 3175-3185.	2.9	15
32	Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. Journal of Experimental Medicine, 2006, 203, 2033-2042.	8.5	49
33	Deliberate removal of T cell help improves virus-neutralizing antibody production. Nature Immunology, 2004, 5, 934-942.	14.5	85
34	Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12883-12888.	7.1	59
35	Observation of Measles Virus Cell-to-Cell Spread in Astrocytoma Cells by Using a Green Fluorescent Protein-Expressing Recombinant Virus. Journal of Virology, 1999, 73, 9568-9575.	3.4	183